Hospital admissions due to immuno-oncology therapy associated toxicity: A retrospective analysis at two tertiary oncology centres. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I.

Patients with a urinary pH of less than 5.5 are more likely to experience tumor recurrence after mitomycin C (MMC) treatment for non-muscle-invasive bladder cancer than those with more-alkaline urine, ...